Interim analysis of a phase 3 trial in 318 adults with IgA nephropathy: at 39 weeks telitacicept cut urine protein-to-creatinine ratio by 58.9% vs 8.8% with placebo (relative difference -55.0%); adverse events 89.3% vs 78.6%, serious 2.5% vs 8.2%.
RCTn = 318
Lv et al. Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial